Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rory Collins

Showing results (71-80 of 267) with videos related to

Pageof 27
Sort By:
Trials|March 4, 2023
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trialSarah Parish, Georgina Buck, Theingi Aung, et al.
International Journal of Epidemiology|March 25, 2006
Cohort profile: the Mexico City Prospective StudyRoberto Tapia-Conyer, Pablo Kuri-Morales, Jesús Alegre-Díaz, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|May 23, 2012
[The China Kadoorie Biobank: related methodology and baseline characteristics of the participants]Li-ming Li, Jun Lv, Yu Guo, et al.
Circulation|April 28, 2012
Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection StudySarah Parish, Alison Offer, Robert Clarke, et al.
The American Journal of Clinical Nutrition|May 11, 2007
Is birth weight a risk factor for ischemic heart disease in later life?Rachel Huxley, Christopher G Owen, Peter H Whincup, et al.
Stroke|February 2, 2008
Body mass index, blood pressure, and mortality from stroke: a nationally representative prospective study of 212,000 Chinese menMaigeng Zhou, Alison Offer, Gonghuan Yang, et al.
International Journal of Epidemiology|July 28, 2006
Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'Bernard Keavney, John Danesh, Sarah Parish, et al.
Circulation. Cardiovascular Quality and Outcomes|July 14, 2016
Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare CostsSeamus Kent, Richard Haynes, Jemma C Hopewell, et al.
Clinical Trials (London, England)|February 20, 2008
Sensible guidelines for the conduct of large randomized trialsSalim Yusuf, Jackie Bosch, Philip J Devereaux, et al.
Lancet (London, England)|October 18, 2002
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic reviewKoon K Teo, Salim Yusuf, Marc Pfeffer, et al.
Pageof 27

Showing results (71-80 of 267) with videos related to

Sort By:
Pageof 27
Trials|March 4, 2023
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trialSarah Parish, Georgina Buck, Theingi Aung, et al.
International Journal of Epidemiology|March 25, 2006
Cohort profile: the Mexico City Prospective StudyRoberto Tapia-Conyer, Pablo Kuri-Morales, Jesús Alegre-Díaz, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|May 23, 2012
[The China Kadoorie Biobank: related methodology and baseline characteristics of the participants]Li-ming Li, Jun Lv, Yu Guo, et al.
Circulation|April 28, 2012
Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection StudySarah Parish, Alison Offer, Robert Clarke, et al.
The American Journal of Clinical Nutrition|May 11, 2007
Is birth weight a risk factor for ischemic heart disease in later life?Rachel Huxley, Christopher G Owen, Peter H Whincup, et al.
Stroke|February 2, 2008
Body mass index, blood pressure, and mortality from stroke: a nationally representative prospective study of 212,000 Chinese menMaigeng Zhou, Alison Offer, Gonghuan Yang, et al.
International Journal of Epidemiology|July 28, 2006
Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'Bernard Keavney, John Danesh, Sarah Parish, et al.
Circulation. Cardiovascular Quality and Outcomes|July 14, 2016
Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare CostsSeamus Kent, Richard Haynes, Jemma C Hopewell, et al.
Clinical Trials (London, England)|February 20, 2008
Sensible guidelines for the conduct of large randomized trialsSalim Yusuf, Jackie Bosch, Philip J Devereaux, et al.
Lancet (London, England)|October 18, 2002
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic reviewKoon K Teo, Salim Yusuf, Marc Pfeffer, et al.
Pageof 27